Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTO0303 for Cycloplegic Refraction in Pediatric Subjects
NCT06609525Phase 3Recruiting
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Refractive errors (RE) (3 arms), sponsored by Taejoon Pharmaceutical Co., Ltd. Primary endpoint: Pupillary dilation effect at 30 minutes after administration. Started May 2024; status: recruiting.
02
Conditions
Refractive errors (RE)
Beyond the preview
Go deeper on NCT06609525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06609525.